Abstract
Background Combination therapy has been proposed in treatment algorithms for idiopathic pulmonary arterial hypertension (IPAH), so the additional effects of bosentan in IPAH patients already treated with high-dose cpoprostcnol (EPO) was evaluated in the present study. Methods and Results Bosentan (62.5 mg twice daily) was administered to 8 IPAH patients already being treated with high-dose EPO (average dose 99.6 ± 43.4 ng · kg-1 · min-1). Hemodynamics were assessed at baseline and at 2 days and then 1 year after the initiation of bosentan. Because a remarkable elevation of mixed venous oxygen saturation was observed at the initiation of bosentan, the dosage of EPO was reduced in 7 patients (from 99,6 ± 43.4 to 82.8 ± 31.3 ng · kg-1 · minl, p
| Original language | English |
|---|---|
| Pages (from-to) | 1142-1146 |
| Number of pages | 5 |
| Journal | Circulation Journal |
| Volume | 72 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - 2008 |
| Externally published | Yes |
Fingerprint
Keywords
- Bosentan
- Combination therapy
- Epoprostenol
- Idiopathic pulmonary arterial hypertension
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Physiology
Cite this
Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. / Akagi, Satoshi; Matsubara, Hiromi; Miyaji, Katsumasa; Ikeda, Etsuko; Dan, Kazuhiro; Tokunaga, Naoto; Hisamatsu, Kenichi; Munemasa, Mitsuru; Fujimoto, Yoshihisa; Ohe, Tohru.
In: Circulation Journal, Vol. 72, No. 7, 2008, p. 1142-1146.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol
AU - Akagi, Satoshi
AU - Matsubara, Hiromi
AU - Miyaji, Katsumasa
AU - Ikeda, Etsuko
AU - Dan, Kazuhiro
AU - Tokunaga, Naoto
AU - Hisamatsu, Kenichi
AU - Munemasa, Mitsuru
AU - Fujimoto, Yoshihisa
AU - Ohe, Tohru
PY - 2008
Y1 - 2008
N2 - Background Combination therapy has been proposed in treatment algorithms for idiopathic pulmonary arterial hypertension (IPAH), so the additional effects of bosentan in IPAH patients already treated with high-dose cpoprostcnol (EPO) was evaluated in the present study. Methods and Results Bosentan (62.5 mg twice daily) was administered to 8 IPAH patients already being treated with high-dose EPO (average dose 99.6 ± 43.4 ng · kg-1 · min-1). Hemodynamics were assessed at baseline and at 2 days and then 1 year after the initiation of bosentan. Because a remarkable elevation of mixed venous oxygen saturation was observed at the initiation of bosentan, the dosage of EPO was reduced in 7 patients (from 99,6 ± 43.4 to 82.8 ± 31.3 ng · kg-1 · minl, p
AB - Background Combination therapy has been proposed in treatment algorithms for idiopathic pulmonary arterial hypertension (IPAH), so the additional effects of bosentan in IPAH patients already treated with high-dose cpoprostcnol (EPO) was evaluated in the present study. Methods and Results Bosentan (62.5 mg twice daily) was administered to 8 IPAH patients already being treated with high-dose EPO (average dose 99.6 ± 43.4 ng · kg-1 · min-1). Hemodynamics were assessed at baseline and at 2 days and then 1 year after the initiation of bosentan. Because a remarkable elevation of mixed venous oxygen saturation was observed at the initiation of bosentan, the dosage of EPO was reduced in 7 patients (from 99,6 ± 43.4 to 82.8 ± 31.3 ng · kg-1 · minl, p
KW - Bosentan
KW - Combination therapy
KW - Epoprostenol
KW - Idiopathic pulmonary arterial hypertension
UR - http://www.scopus.com/inward/record.url?scp=46849106308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46849106308&partnerID=8YFLogxK
U2 - 10.1253/circj.72.1142
DO - 10.1253/circj.72.1142
M3 - Article
C2 - 18577825
AN - SCOPUS:46849106308
VL - 72
SP - 1142
EP - 1146
JO - Circulation Journal
JF - Circulation Journal
SN - 1346-9843
IS - 7
ER -